Table 1 Patient characteristics

Age, median (SD)

49 (13)

Sex, % female

65.6%

Smoking status (% never smokers)^a

73.2%

ECOG PS (%) at baseline^b

0

8

1

31

2

1

Histology (%)

Adenocarcinoma

49/50^c

Chemotherapy

52/61

ALK TKI, patient number

Crizotinib

61

Metastasis

Brain^d

33/49

Bone^e

31/55

Follow-up in months (median, [IQR])

52.4 (38.0–82.43)

Cases with baseline samples

61

Cases with disease progression samples

15